Melanoma

Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells
Rachel E Beard, Zhili Zheng, Kiran H Lagisetty, William R Burns, Eric Tran, Stephen M Hewitt, Daniel Abate-Daga, Shannon F Rosati, Howard A Fine, Soldano Ferrone, Steven A Rosenberg, Richard A Morgan

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 25; DOI: 10.1186/2051-1426-2-25
High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014
Janice P Dutcher, Douglas J Schwartzentruber, Howard L Kaufman, Sanjiv S Agarwala, Ahmad A Tarhini, James N Lowder, Michael B Atkins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 26; DOI: 10.1186/s40425-014-0026-0
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series
Sowmya Ravi, Kristen Spencer, Mary Ruisi, Nageatte Ibrahim, Jason J Luke, John A Thompson, Keisuke Shirai, David Lawson, Heddy Bartell, Ragini Kudchadkar, Ngoc Thi Gunter, Janice M Mehnert, Evan J Lipson

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 33; DOI: 10.1186/s40425-014-0033-1
Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome
Mizuki Nishino, Anita Giobbie-Hurder, Nikhil H Ramaiya, F Stephen Hodi

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 40; DOI: 10.1186/s40425-014-0040-2
Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma
Joshua S Manusow, Leila Khoja, Nataly Pesin, Anthony M Joshua, Efrem D Mandelcorn

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 41; DOI: 10.1186/s40425-014-0041-1
Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program
Roxanne Payne, Lyn Glenn, Helena Hoen, Beverley Richards, John W Smith, Robert Lufkin, Todd S Crocenzi, Walter J Urba, Brendan D Curti

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 13; DOI: 10.1186/2051-1426-2-13
Implementation of an Interleukin-2 National Registry: an opportunity to improve cancer outcomes
Michael K Wong, Howard L Kaufman, Gregory A Daniels, David F McDermott, Sandra Aung, James N Lowder, Michael A Morse

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 20; DOI: 10.1186/2051-1426-2-20
Opportunistic infections in patients treated with immunotherapy for cancer
Chrisann Kyi, Matthew D Hellmann, Jedd D Wolchok, Paul B Chapman, Michael A Postow

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 19; DOI: 10.1186/2051-1426-2-19
Ipilimumab in patients with melanoma and autoimmune disease
Chrisann Kyi, Richard D Carvajal, Jedd D Wolchok, Michael A Postow

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (1) 35; DOI: 10.1186/s40425-014-0035-z
KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Pier Francesco Ferrucci, Anna Maria Di Giacomo, Michele Del Vecchio, Victoria Atkinson, Henrik Schmidt, Jacob Schachter, Paola Queirolo, Georgina V Long, Rosalie Stephens, Inge Marie Svane, Michal Lotem, Mahmoud Abu-Amna, Eduard Gasal, Razi Ghori, Scott J Diede, Elizabeth S Croydon, Antoni Ribas, Paolo Antonio Ascierto

Journal for ImmunoTherapy of Cancer Dec 2020, 8 (2) e001806; DOI: 10.1136/jitc-2020-001806

Main menu

Melanoma

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Melanoma

Pages